We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+10.58%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$604M
AUM Growth
-$93M
(-13%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-22.99%
Top 10 Holdings %
Top 10 Hldgs %
48.64%
Holding
92
New
16
Increased
10
Reduced
22
Closed
33
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$29.3M |
| 2 |
Globus Medical
GMED
|
+$25.7M |
| 3 |
Cencora
COR
|
+$21M |
| 4 |
Cigna
CI
|
+$16.3M |
| 5 |
Viatris
VTRS
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$27.8M |
| 2 |
Corcept Therapeutics
CORT
|
+$27.2M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$27.1M |
| 4 |
LivaNova
LIVN
|
+$26.8M |
| 5 |
Embecta
EMBC
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.2% |
| 2 | Industrials | 6.36% |
| 3 | Miscellaneous | 3.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
EyePoint Inc
EYPT
$258M
| $8.91M | 1.47% |
623,130
-98,655
| -14% | -$1.32M |
2026 Q1
1 quarter
|
|
|
HELP
27
Helus Pharma Inc. Common Stock
HELP
$771M
| $8.59M | 1.42% |
+1,300,000
| New | +$6.5M |
2026 Q2
0 quarters
|
|
28
ANI Pharmaceuticals
ANIP
$1.66B
| $8.05M | 1.33% |
97,305
-168,238
| -63% | -$13.5M |
2024 Q4
6 quarters
|
|
29
Protara Therapeutics
TARA
$137M
| $7.34M | 1.21% |
1,921,872
-47,967
| -2% | -$228K |
2025 Q4
2 quarters
|
|
30
Relmada Therapeutics
RLMD
$331M
| $6.94M | 1.15% |
1,003,562
+38,562
| +4% | +$269K |
2026 Q1
1 quarter
|
|
31
Tango Therapeutics
TNGX
$3.72B
| $6.52M | 1.08% |
+208,500
| New | +$5.15M |
2026 Q2
0 quarters
|
|
32
Aquestive Therapeutics
AQST
$474M
| $6.18M | 1.02% |
1,486,175
-436,712
| -23% | -$1.84M |
2025 Q1
5 quarters
|
|
|
33
Dianthus Therapeutics
DNTH
$4.03B
| $5.78M | 0.96% |
59,254
-310,791
| -84% | -$27.1M |
2025 Q1
5 quarters
|
|
34
Sionna Therapeutics
SION
$176M
| $5.62M | 0.93% |
127,808
-166,532
| -57% | -$6.66M |
2026 Q1
1 quarter
|
|
35
Ocular Therapeutix
OCUL
$1.51B
| $5.3M | 0.88% |
539,493
-429,104
| -44% | -$3.89M |
2026 Q1
1 quarter
|
|
36
Zenas BioPharma
ZBIO
$1.62B
| $5.29M | 0.88% |
208,557
-123,173
| -37% | -$2.45M |
2026 Q1
1 quarter
|
|
37
Bright Minds Biosciences
DRUG
$506M
| $5.19M | 0.86% |
73,952
-12,131
| -14% | -$953K |
2024 Q4
6 quarters
|
|
38
OnKure Therapeutics
OKUR
$85M
| $4.92M | 0.81% |
1,078,965
| – | – |
2026 Q1
1 quarter
|
|
39
Savara
SVRA
$914M
| $3.8M | 0.63% |
617,675
+3,787
| +0.6% | +$20.3K |
2024 Q4
6 quarters
|
|
40
PMV Pharmaceuticals
PMVP
$64.7M
| $3.53M | 0.58% |
2,634,137
-442,443
| -14% | -$568K |
2024 Q2
8 quarters
|
|
41
Aveanna Healthcare
AVAH
$2.69B
| $3.16M | 0.52% |
+369,036
| New | +$2.6M |
2026 Q2
0 quarters
|
|
42
Ovid Therapeutics
OVID
$420M
| $2.7M | 0.45% |
1,005,334
-247,047
| -20% | -$637K |
2024 Q4
6 quarters
|
|
43
Immunome
IMNM
$1.94B
| $2.63M | 0.44% |
124,168
-40,942
| -25% | -$876K |
2026 Q1
1 quarter
|
|
44
CALL
Hims & Hers Health
HIMS
$6.55B
| $2.6M | 0.43% |
+75,000
| New | +$2.01M |
2026 Q2
0 quarters
|
|
45
AN2 Therapeutics
ANTX
$128M
| $2.56M | 0.42% |
529,933
-127,267
| -19% | -$547K |
2026 Q1
1 quarter
|
|
46
Serina Therapeutics
SER
$43.7M
| $1.94M | 0.32% |
1,000,000
| – | – |
2026 Q1
1 quarter
|
|
47
Aligos Therapeutics
ALGS
$30.3M
| $1.89M | 0.31% |
327,237
| – | – |
2025 Q1
5 quarters
|
|
48
iBio
IBIO
$49.3M
| $1.58M | 0.26% |
904,268
| – | – |
2025 Q4
2 quarters
|
|
49
Xilio Therapeutics
XLO
$56.3M
| $1.46M | 0.24% |
152,464
| – | – |
2025 Q4
2 quarters
|
|
50
Artivion
AORT
$1.06B
| $1.09M | 0.18% |
+48,481
| New | +$1.36M |
2026 Q2
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sio Capital Management held 92 positions worth $604M, down 13% from $697M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sio Capital Management withdrew a net $139M in Q2 2026, closing 33 positions and reducing 22 holdings. Its most notable exit was Corcept Therapeutics, an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, Sio Capital Management opened a new position in Allogene Therapeutics worth $27.7M.
- Sio Capital Management's largest Q2 2026 buy was Allogene Therapeutics: 13,323,431 shares worth $27.7M.
- Sio Capital Management added most to Cencora in Q2 2026, an estimated $21M increase.
- Sio Capital Management's biggest Q2 2026 reduction was Icon, cutting an estimated $27.8M.
- Sio Capital Management fully exited Corcept Therapeutics in Q2 2026, selling an estimated $27.2M.
- Sio Capital Management's ten largest holdings make up 49% of its $604M portfolio in Q2 2026.
- Sio Capital Management opened 16 new positions and closed 33 in Q2 2026.
- Sio Capital Management's portfolio value fell 13% quarter-over-quarter to $604M.
Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.